Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -19.32
- Piotroski Score 2.00
- Grade Buy
- Symbol (GLMD)
- Company Galmed Pharmaceuticals Ltd.
- Price $3.36
- Changes Percentage (3.55%)
- Change $0.12
- Day Low $3.24
- Day High $3.38
- Year High $23.80
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/19/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.65
- Trailing P/E Ratio -0.21
- Forward P/E Ratio -0.21
- P/E Growth -0.21
- Net Income $-6,912,000
Income Statement
Quarterly
Annual
Latest News of GLMD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
GLMD Stock Price | Galmed Pharmaceuticals Ltd. Stock Quote (U.S.: Nasdaq) | MarketWatch
Galmed Pharmaceuticals is a biopharmaceutical company focused on developing oral therapy for non-alcoholic steato-hepatitis (NASH) treatment. Their product Aramchol targets overweight or obese patient...
By MarketWatch | 1 month ago -
Galmed Pharmaceuticals Ltd. (GLMD) Stock Price, News, Quote & History - Yahoo Finance
Consider investing in penny stocks with strong buy ratings on Wall Street for potential growth. These stocks are priced under $5 per share, offering high volatility and possible rapid gains or losses....
By Yahoo! Finance | 1 month ago
